(-)-Epigallocatechin-3-gallate inhibits Hsp90 function by impairing Hsp90 association with cochaperones in pancreatic cancer cell line mia paca-2

Molecular Pharmaceutics

Volumn 6, Issue 4, 2009, Pages 1152-1159

  Li, Yanyan ^a,b   Zhang, Tao ^b   Jiang, Yiqun ^b   Lee, Hsiu Fang ^b   Schwartz, Steven J ^a   Sun, Duxin ^b  

^a OHIO STATE UNIVERSITY   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

( ) EGCG; ATP; Cochaperone; Hsp90; Pancreatic cancer cell

Indexed keywords

ADENOSINE TRIPHOSPHATE; CASPASE 3; CYCLIN DEPENDENT KINASE 4; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIGALLOCATECHIN GALLATE; HEAT SHOCK COGNATE PROTEIN 70; HEAT SHOCK PROTEIN 90; PROTEIN KINASE B; PROTEIN P23; RAF PROTEIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CARBOXY TERMINAL SEQUENCE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DEGRADATION; DOWN REGULATION; DRUG PROTEIN BINDING; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IC 50; IMMUNOPRECIPITATION; IN VITRO STUDY; MITOSIS INHIBITION; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; WESTERN BLOTTING;

ADENOSINE TRIPHOSPHATE; ANTICARCINOGENIC AGENTS; BLOTTING, WESTERN; CATECHIN; CELL LINE, TUMOR; CELL PROLIFERATION; HSC70 HEAT-SHOCK PROTEINS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; IMMUNOPRECIPITATION; PANCREATIC NEOPLASMS;

EID: 68249097417     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp900037p     Document Type: Article

References (47)

1. Jemal, A.; Siegel, R.; Ward, E.; Murray, T.; Xu, J.; Thun, M. J. Cancer statistics, 2007. CA - Cancer J. Clin. 2007, 57 (1), 43-66.
2. Ghaneh, P.; Costello, E.; Neoptolemos, J. P. Biology and management of pancreatic cancer. Gut 2007, 56 (8), 1134-1152
3. Korc, M.; Chandrasekar, B.; Yamanaka, Y.; Friess, H.; Buchier, M.; Beger, H. G. Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor alpha. J. Clin. Invest. 1992, 90 (4), 1352-1360
4. Yamanaka, Y.; Friess, H.; Kobrin, M. S.; Buchler, M.; Kunz, J.; Beger, H. G.; Korc, M. Overexpression of HER2/neu oncogene in human pancreatic carcinoma. Hum. Pathol. 1993, 24 (10), 1127-1134 (Pubitemid 23306246)
5. Schlieman, M. G.; Fahy, B. N.; Ramsamooj, R.; Beckett, L.; Bold, R. J. Incidence, mechanism and prognostic value of activated AKT in pancreas cancer. Br. J. Cancer 2003, 89 (11), 2110-2115
6. Prodromou, C.; Roe, S. M.; O'Brien, R.; Ladbury, J. E.; Piper, P. W.; Pearl, L. H. Identification and structural characterization of the ATP/ADP-binding site in the Hsp90 molecular chaperone. Cell 1997, 90 (1), 65-75.
7. Westerheide, S. D.; Morimoto, R. I. Heat shock response modulators as therapeutic tools for diseases of protein conformation. J. Biol. Chem. 2005, 280 (39), 33097-33100
8. Welch, W. J. The role of heat-shock proteins as molecular chaperones. Curr. Opin. Cell Biol. 1991, 3 (6), 1033-1038
9. McClellan, A. J.; Xia, Y.; Deutschbauer, A. M.; Davis, R. W.; Gerstein, M.; Frydman, J. Diverse cellular functions of the Hsp90 molecular chaperone uncovered using systems approaches. Cell 2007, 131 (1), 121-135 (Pubitemid 47498528)
10. Falsone, S. F.; Gesslbauer, B.; Tirk, F.; Piccinini, A. M.; Kungl, A. J. A proteomic snapshot of the human heat shock protein 90 interactome. FEBS Lett. 2005, 579 (28), 6350-6354
11. Kamal, A.; Boehm, M. F.; Burrows, F. J. Therapeutic and diagnostic implications of Hsp90 activation. Trends Mol. Med. 2004, 10 (6), 283-290 (Pubitemid 38725896)
12. Pearl, L. H.; Prodromou, C.; Workman, P. The Hsp90 molecular chaperone: an open and shut case for treatment. Biochem. J. 2008, 410 (3), 439-453
13. Didelot, C.; Lanneau, D.; Brunet, M.; Joly, A. L.; De Thonel, A.; Chiosis, G.; Garrido, C. Anti-cancer therapeutic approaches based on intracellular and extracellular heat shock proteins. Curr. Med. Chem. 2007, 14 (27), 2839-2847 (Pubitemid 350201651)
14. Ali, M. M.; Roe, S. M.; Vaughan, C. K.; Meyer, P.; Panaretou, B.; Piper, P. W.; Prodromou, C.; Pearl, L. H. Crystal structure of an Hsp90-nucleotide-p23/ Sba1 closed chaperone complex. Nature 2006, 440 (7087), 1013-1017
15. Scheibel, T.; Neuhofen, S.; Weikl, T.; Mayr, C.; Reinstein, J.; Vogel, P. D.; Buchner, J. ATP-binding properties of human Hsp90. J. Biol. Chem. 1997, 272 (30), 18608-18613
16. Workman, P. Altered states: selectively drugging the Hsp90 cancer chaperone. Trends Mol. Med. 2004, 10 (2), 47-51. (Pubitemid 38210022)
17. Solit, D. B.; Ivy, S. P.; Kopil, C.; Sikorski, R.; Morris, M. J.; Slovin, S. F.; Kelly, W. K.; DeLaCruz, A.; Curley, T.; Heller, G.; Larson, S.; Schwartz, L.; Egorin, M. J.; Rosen, N.; Scher, H. I. Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. Clin. Cancer Res. 2007, 13 (6), 1775-1782 (Pubitemid 46952945)
18. Neckers, L. Development of small molecule Hsp90 Inhibitors: utilizing both forward and reverse chemical genomics for drug identification. Curr. Med. Chem. 2003, 10 (9), 733-739. (Pubitemid 36443229)
19. Roe, S. M.; Prodromou, C.; O'Brien, R.; Ladbury, J. E.; Piper, P. W.; Pearl, L. H. Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin. J. Med. Chem. 1999, 42 (2), 260-266
20. Neckers, L. Chaperoning oncogenes: Hsp90 as a target of geldanamycin. Handb. Exp. Pharmacol. 2006, (172), 259-277
21. Prodromou, C.; Siligardi, G.; O'Brien, R.; Woolfson, D. N.; Regan, L.; Panaretou, B.; Ladbury, J. E.; Piper, P. W.; Pearl, L. H. Regulation of Hsp90 ATPase activity by tetratricopeptide repeat (TPR)-domain co-chaperones. EMBO J. 1999, 18 (3), 754-762
22. Terasawa, K.; Minami, M.; Minami, Y. Constantly updated knowledge of Hsp90. J. Biochem. 2005, 137 (4), 443-447
23. Marcu, M. G.; Chadli, A.; Bouhouche, I.; Catelli, M.; Neckers, L. M. The heat shock protein 90 antagonist novobiocin interacts with a previously unrecognized ATP-binding domain in the carboxyl terminus of the chaperone. J. Biol. Chem. 2000, 275 (47), 37181-37186
24. Yun, B. G.; Huang, W.; Leach, N.; Hartson, S. D.; Matts, R. L. Novobiocin induces a distinct conformation of Hsp90 and alters Hsp90-cochaperone-client interactions. Biochemistry 2004, 43 (25), 8217-8229
25. Marcu, M. G.; Schulte, T. W.; Neckers, L. Novobiocin and related coumarins and depletion of heat shock protein 90-dependent signaling proteins. J. Natl. Cancer Inst. 2000, 92 (3), 242-248
26. Landis-Piwowar, K. R.; Huo, C.; Chen, D.; Milacic, V.; Shi, G.; Chan, T. H.; Dou, Q. P. A novel prodrug of the green tea polyphenol (-)-epigallocatechin- 3-gallate as a potential anticancer agent. Cancer Res. 2007, 67 (9), 4303-4310
27. Fujiki, H. Two stages of cancer prevention with green tea. J. Cancer. Res. Clin. Oncol. 1999, 125 (11), 589-597 (Pubitemid 29502339)
28. Palermo, C. M.; Westlake, C. A.; Gasiewicz, T. A. Epigallocatechin gallate inhibits aryl hydrocarbon receptor gene transcription through an indirect mechanism involving binding to a 90 kDa heat shock protein. Biochemistry 2005, 44 (13), 5041-5052
29. Khan, N.; Afaq, F.; Saleem, M.; Ahmad, N.; Mukhtar, H. Targeting multiple signaling pathways by green tea polyphenol (-)-epigallocatechin-3-gallate. Cancer Res. 2006, 66 (5), 2500-2505
30. Yang, C. S.; Maliakal, P.; Meng, X. Inhibition of carcinogenesis by tea. Annu. Rev. Pharmacol. Toxicol. 2002, 42, 25-54. (Pubitemid 34160518)
31. Adhami, V. M.; Siddiqui, I. A.; Ahmad, N.; Gupta, S.; Mukhtar, H. Oral consumption of green tea polyphenols inhibits insulin-like growth factor-I-induced signaling in an autochthonous mouse model of prostate cancer. Cancer Res. 2004, 64 (23), 8715-8722 (Pubitemid 39552088)
32. Nagle, D. G.; Ferreira, D.; Zhou, Y. D. Epigallocatechin-3-gallate (EGCG): chemical and biomedical perspectives. Phytochemistry 2006, 67 (17), 1849-1855
33. Ahmad, N.; Feyes, D. K.; Nieminen, A. L.; Agarwal, R.; Mukhtar, H. Green tea constituent epigallocatechin-3-gallate and induction of apoptosis and cell cycle arrest in human carcinoma cells. J. Natl. Cancer Inst. 1997, 89 (24), 1881-1886 (Pubitemid 28009824)
34. Shimizu, M.; Deguchi, A.; Lim, J. T.; Moriwaki, H.; Kopelovich, L.; Weinstein, I. B. (-)-Epigallocatechin gallate and polyphenon E inhibit growth and activation of the epidermal growth factor receptor and human epidermal growth factor receptor-2 signaling pathways in human colon cancer cells. Clin. Cancer Res. 2005, 11 (7), 2735-2746
35. Jatoi, A.; Ellison, N.; Burch, P. A.; Sloan, J. A.; Dakhil, S. R.; Novotny, P.; Tan, W.; Fitch, T. R.; Rowland, K. M.; Young, C. Y.; Flynn, P. J. A phase II trial of green tea in the treatment of patients with androgen independent metastatic prostate carcinoma. Cancer 2003, 97 (6), 1442-1446 (Pubitemid 36297774)
36. Solit, D. B.; Chiosis, G. Development and application of Hsp90 inhibitors. Drug Discovery Today 2008, 13 (1-2), 38-43.
37. Powers, M. V.; Workman, P. Inhibitors of the heat shock response: biology and pharmacology. FEBS Lett. 2007, 581 (19), 3758-3769 (Pubitemid 47081010)
38. Chiosis, G.; Neckers, L. Tumor selectivity of Hsp90 inhibitors: the explanation remains elusive. ACS Chem. Biol. 2006, 1 (5), 279-284
39. Blagg, B. S.; Kerr, T. D. Hsp90 inhibitors: small molecules that transform the Hsp90 protein folding machinery into a catalyst for protein degradation. Med. Res. Rev. 2006, 26 (3), 310-338
40. Allan, R. K.; Mok, D.; Ward, B. K.; Ratajczak, T. Modulation of chaperone function and cochaperone interaction by novobiocin in the C-terminal domain of Hsp90: evidence that coumarin antibiotics disrupt Hsp90 dimerization. J. Biol. Chem. 2006, 281 (11), 7161-7171 (Pubitemid 43847481)
41. Garnier, C.; Lafitte, D.; Tsvetkov, P. O.; Barbier, P.; Leclerc-Devin, J.; Millot, J. M.; Briand, C.; Makarov, A. A.; Catelli, M. G.; Peyrot, V. Binding of ATP to heat shock protein 90: evidence for an ATP-binding site in the C-terminal domain. J. Biol. Chem. 2002, 277 (14), 12208-12214 (Pubitemid 34952787)
42. Ishii, T.; Mori, T.; Tanaka, T.; Mizuno, D.; Yamaji, R.; Kumazawa, S.; Nakayama, T.; Akagawa, M. Covalent modification of proteins by green tea polyphenol (-)-epigallocatechin-3-gallate through autoxidation. Free Radical Biol. Med. 2008, 45 (10), 1384-1394
43. Young, J. C.; Obermann, W. M.; Hartl, F. U. Specific binding of tetratricopeptide repeat proteins to the C-terminal 12-kDa domain of hsp90. J. Biol. Chem. 1998, 273 (29), 18007-18010
44. Fang, Y.; Fliss, A. E.; Rao, J.; Caplan, A. J. SBA1 encodes a yeast hsp90 cochaperone that is homologous to vertebrate p23 proteins. Mol. Cell. Biol. 1998, 18 (7), 3727-3734
45. Yin, Z.; Henry, E. C.; Gasiewicz, T. A. (-)-Epigallocatechin-3-gallate is a novel Hsp90 inhibitor. Biochemistry 2009, 48 (2), 336-345
46. Kaur, J.; Ralhan, R. Induction of apoptosis by abrogation of HSP70 expression in human oral cancer cells. Int. J. Cancer 2000, 85 (1), 1-5.
47. Schmitt, E.; Maingret, L.; Puig, P. E.; Rerole, A. L.; Ghiringhelli, F.; Hammann, A.; Solary, E.; Kroemer, G.; Garrido, C. Heat shock protein 70 neutralization exerts potent antitumor effects in animal models of colon cancer and melanoma. Cancer Res. 2006, 66 (8), 4191-4197